Pinealon
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Synthetic pineal tripeptide (Glu-Asp-Arg) bioregulator that penetrates the blood-brain barrier, providing neuroprotection via oxidative stress suppression and gene expression modulation in neurons.
Methodological Note: >95% of published research on this peptide originates from the Khavinson bioregulation group (Institute of Bioregulation and Gerontology, St. Petersburg). Independent replication by Western laboratories is lacking. All evidence should be interpreted with this single-group limitation in mind.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | EDR, Glu-Asp-Arg (Note: Cortagen is a different Khavinson peptide — AEDP) |
| Category | Neuroprotection / Cognitive / Anti-Aging / Sleep |
| Sequence | Glu-Asp-Arg (3 amino acids) |
| Molecular Weight | ~402.4 Da |
| Molecular Formula | C13H22N4O8 |
| PubChem CID | 16133850 |
| Administration | SubQ / Intranasal / Oral |
| Typical Dose Range | 1-10 mg/day |
| Half-Life | Short (minutes; typical of tripeptides) |
| Storage | Lyophilized: -20C long-term; 2-8C short-term. Reconstituted: 2-8C for 2-4 weeks |
| FDA Status | Research only (developed in Russia; not submitted for FDA review) |
| WADA Status | Not listed |
Mechanism of Action
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) originally developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It is derived from the amino acid sequence of the pineal gland peptide fraction and belongs to the class of short peptide bioregulators — small peptides (2-4 amino acids) that are proposed to modulate gene expression by directly interacting with DNA and chromatin structures.
The primary neuroprotective mechanism involves suppression of reactive oxygen species (ROS) in neurons. In cortical neuron cultures, pinealon significantly increased cell viability under oxidative stress conditions by reducing free radical levels in a dose-dependent manner (PMID: 21978084). This antioxidant effect is proposed to be mediated through upregulation of endogenous antioxidant enzyme gene expression rather than direct radical scavenging.
In an in vitro model of Alzheimer's disease (amyloid beta-induced synaptotoxicity), pinealon (EDR) at 200 ng/ml increased the number of mushroom dendritic spines — the structural correlate of long-term memory — by 71%, restoring them to near-normal levels (PMID: 28853087). Mushroom spines are the most functionally important spine type for stable synaptic connections.
In vivo, pinealon improved cognitive function in rat offspring exposed to prenatal hyperhomocysteinemia, enhancing spatial orientation, learning ability, and neuronal resistance to oxidative stress (PMID: 22567179).
As a pineal-derived peptide, pinealon is also proposed to support circadian rhythm regulation and melatonin pathway function, consistent with the broader Khavinson peptide bioregulation theory that tissue-specific short peptides can restore age-related functional decline in their organs of origin.
Important methodological note: The vast majority of pinealon research originates from a single research group (Khavinson's laboratory). Independent international replication of these findings remains a critical gap.
Key Research Areas
- Neuroprotection — Suppression of oxidative stress and free radical damage in neurons (PMID: 21978084)
- Alzheimer's disease — Restoration of dendritic spine morphology under amyloid synaptotoxicity (PMID: 28853087)
- Developmental neuroprotection — Cognitive protection in animal models of prenatal neurotoxicity (PMID: 22567179)
- Aging and gerontology — Clinical use in elderly patients with organic brain syndrome (PMID: 26390612)
- Retinal neuroprotection — Protection of retinal ganglion cells in aging and disease models
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 0 | No controlled human trials |
| Human observational | 1 | Clinical use in elderly (Russian, limited methodology) |
| Animal in vivo | 1 | Prenatal hyperhomocysteinemia model |
| In vitro | 2 | Neuron viability, dendritic spine restoration |
| Systematic reviews | 0 | None published |
Clinical Applications
- Cognitive Enhancement — Age-related cognitive decline support
- Neuroprotection — Neuronal protection from oxidative stress and degeneration
- Sleep Disorders — Pineal peptide-mediated circadian rhythm support
- Anti-Aging — Epigenetic regulation and neuroprotective geroprotection
Protocols Using This Peptide
Ageless Peps Products
- AP-Pinealon-Vial — Pinealon 10mg Vial
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ | 1-10 mg | Once daily | 10-14 days (Russian cycle) | Khavinson bioregulator protocols |
| Intranasal | 1-5 mg | Once daily | 10-14 days | Russian clinical practice |
| Oral | 1-10 mg | Once daily | 4-6 weeks | Alternative protocol |
| In vitro | 200 ng/ml | N/A | N/A | PMID 28853087 (spine study) |
Cycling
Traditional Russian bioregulator protocol: 10-14 day treatment courses, repeated every 3-6 months. This pulsed approach is based on the theory that short peptides "reset" gene expression patterns and the effects persist after discontinuation. Some practitioners use longer continuous protocols (4-6 weeks on / 4-6 weeks off) for sustained cognitive support.
Contraindications & Safety
- Contraindications: Active malignancy (theoretical — gene expression modulation); autoimmune CNS conditions (limited data)
- Common side effects: Minimal reported; rare mild headache with intranasal route. Tripeptides are generally well-tolerated due to small size and endogenous-like structure.
- Drug interactions: Unknown; no formal interaction studies conducted
- Pregnancy/nursing: Contraindicated (no reproductive safety data)
- Special populations: Limited safety data in any population. All data from Russian clinical practice and Khavinson group research. The single-source research base is a significant limitation for safety characterization.
Synergistic Combinations
- Semax + Pinealon — BDNF enhancement (Semax) + neuroprotection (Pinealon)
- Epitalon + Pinealon — Fellow Khavinson bioregulators; pineal support (Pinealon) + telomerase activation (Epitalon)
- Noopept + Pinealon — Cognitive enhancement + neuroprotection stack
- Selank + Pinealon — Anxiolytic neuropeptide + neuroprotective tripeptide
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| PMID-21978084 – Pinealon Increases Cell Viability via Free Radical Suppression | Pinealon increases cell viability by suppression of free radicals | 2011 | In vitro |
| PMID-28853087 – EDR Tripeptide Restores Neuronal Spines Alzheimers Model | Tripeptides restore neuronal spines in Alzheimer's model | 2017 | In vitro |
| PMID-22567179 – Pinealon Protects Offspring from Prenatal Hyperhomocysteinemia | Pinealon protects rat offspring from prenatal hyperhomocysteinemia | 2012 | Animal in vivo |
| 27909961 | Short Peptides Regulate Gene Expression | 2016 | Narrative Review |
| 34834147 | Peptide Regulation of Gene Expression: A Systematic Review | 2021 | Systematic Review |
| 35408963 | Peptides Regulating Proliferative Activity in THP-1 Cell Line | 2022 | In vitro |
References
- PMID 21978084 — Khavinson et al., Adv Gerontol 2011 (cell viability)
- PMID 28853087 — Khavinson et al., Bull Exp Biol Med 2017 (dendritic spines)
- PMID 22567179 — Khavinson et al., Int J Clin Exp Med 2012 (neuroprotection in vivo)
Related
FDA Disclaimer: The products and claims made about specific products have not been evaluated by the United States Food and Drug Administration and are not approved to diagnose, treat, cure, or prevent disease.
Research Note: All pinealon research originates primarily from a single research group (V.K. Khavinson, St. Petersburg Institute of Bioregulation and Gerontology). Independent international replication of findings is needed before clinical conclusions can be drawn.
#peptide #neuroprotection #cognitive #anti-aging #sleep #bioregulator #pineal #EDR #tripeptide #subq #intranasal